SAMHD1 and acute myeloid leukemia: Studies have demonstrated that introducing Vpx into AML cells has been shown to deplete SAMHD1, thereby enhancing the anti-tumor effects of ara-C.1,22 However, while promising, applying this approach in vivo presents significant challenges, such as achieving selective targeting of SAMHD1 in tumor cells without affecting normal cells.